About Us

About Us

Pioneering the Medical Cannabis Industry

BOL Pharma (BOL) has been pioneering the creation of the medical cannabis industry in israel since 2007. The company sources 99% pure pharma grade CBD, THC, and other active ingredients from its own organic GAP certified growing facilities and cGMP certified production plant. Working in conjuction with Israel’s Ministry of Health and under governmental license, BOL serves thousands of patients, doctors, HMOs, and hospitals providing cannabis based medical products and cannabinoid active pharmaceutical ingredients (APIs). As a full service contract manufacturer, BOL produces formulations for clinical research and white label services for the pharmaceuticals, food, supplements, and cosmetics industries.

BOL’s seasoned management team of professionals, medical experts, and researchers bring a wealth of experience and expertise in clinical research, precision agriculture, production and marketing of pharma and health products.

Pharmaceutical Drug Development

BOL Pharma has joined forces with key players to create a unique platform for the development of cannabinoid based drugs. Leveraging Israel’s advanced drug development ecosystem, the company conducts FDA approved clinical trials on its own formulations and offers the same oppotunity to researchers and drug developers. BOL provides cGMP produced APIs, formulations, and sophisticated drug delivery systems as well as a streamlined, highly cost effective process for launching and conducting clinical trials in Israel’s world leading hospitals.

State of the Art Production Facilities

Starting with cutting edge innovation combined with extensive agricultural know-how the company applies precise agro-methodologies enabling complete control of the growth environment. Plants are grown and cultivated in controlled conditions, complying with organic growing protocols and Good Agricultural Practices (GAP). A unique and proprietary combination of monitoring and control methods enables the production of highly consistent botanical based products that deliver optimal medical value.

The company’s end-to-end medical cannabis operation includes handling of finished product, packaging, and climate controlled storage facilites for materials at different stages of production. Based on proprietary patented strains designed to produce specific cannabinoids, plants are cultivated in controlled and automated greenhouses and monitored to ensure harvesting at the peak stage. Post-harvest handling and production is conducted on-site in BOL’s cGMP certified pharma-grade extraction and manufacturing facility.

Board Management

Hagai Hillman – Chairman

Founder & ChairmanHagai has dedicated his career to cultivating and growing export agriculture produce utilizing advanced agriculture technologies and groundbreaking Agro-methodologies. He is the founder and Chairman of the Israeli Licensed Medical Cannabis Growers Association.

He has established multiple relationship and collaborations with local academic institutions developing significantly improved agro-growth methods, plant genetics techniques, chemical stabilization protocols and many other developments all aimed at maximizing medicinal value in botanical produce.

Government licensed grower of medical Cannabis since 2008, Hagai has established an advanced research facility and labs for the cultivation of unique Cannabis genetic strands and production of Botanical Cannabinoids for the Pharma, Medical Cosmetics and Food Supplements industries.

Dr. Tamir Gedo – CEO

Dr. Tamir Gedo serves as the CEO of BOL Pharma, one of Israel’s pioneers driving the worldwide medical cannabis industry. In this capacity, he draws upon 25 years as a marketing and business strategy expert serving in academic, government, and industry functions. A veteran of the Pharma and Nutraceuticals industry, Dr. Gedo has extensive experience sourcing, producing and marketing specialty products.

Dr. Gedo possesses extensive expertise in international marketing, branding, entrepreneurship, and business strategy. As a senior Manager, Dr. Gedo has contributed to a wide range of branding, strategic planning, and market penetration activities of major companies in a variety of industries. As a consultant, Dr. Gedo provided services to companies in the medical, food, nutritional supplements, and pharma industries. In parallel to his business and consulting practice, Dr. Tamir has served as the head of the marketing department and other faculty positions of several colleges in Israel and was a guest lecturer in the Department of Business Administration of Shanghai University.

Over the years, he has taught undergraduate and graduate level courses in global marketing, business strategy, innovation, and entrepreneurship. Dr. Gedo received his PhD in Behavioral Economics from Manchester Business School (UK) and an MBA from Ben Gurion University (Israel). He completed a B.Sc. in Molecular Biology at Bar Ilan University (Israel).

Avner Shekel – COO

Avner has over 25 years of experience of agriculture and agro technology management.

Avner has advanced within BOL undertaking leading positions for the past five years and has a proven track-record of corporate execution in complex projects relating to medical cannabis growth, cultivation and commercialization.

SagiBenRimon

Sagi Ben Rimon- General Manager of BOL Israel

In a career spanning over 20 years, Sagi has held several  leadership positions mainly in the pharma industry. Before joining BOL Pharma, he had completed 14 years with Teva Pharmaceuticals Ltd, where he held several positions of responsibility, including Vice-President, Operations Network strategic planning and Manager of the Kfar Saba Oral Solid Dosages plant, a 900 employee, $100M expense and over $1 Billion revenue pharmaceutical manufacturing plant. Before that Sagi has served as VP R&D and Manufacturing for Optonol, a company specializing in Ophthalmic implants.

Sagi holds an MBA in Business Management as well as a B.Sc in Mechanical engineering, both from the  Ben Gurion university in  Beer Sheba.

 

Scientific Advisory Board

Miki Ofer – Head Pharmacist

Formerly chairman of the Israeli Pharmacists Association and member of its professional committee.

A consultant to major Pharma companies and to the Israeli judicial system.

Dr. Haim Mell – Director of Regulatory Affairs

Dr. Haim Mell holds an MD in Psychotherapy and served as the former head of the Treatment and Rehabilitation Department of Israel’s Anti-Drug Authority. Haim is engaged in various local and international organizations dealing with the challenge of drug addiction. He serves as a member of the board of the European Opiate Addiction Treatment Association and cofounded the Israeli branch of the International Society of Addiction Medicine. Haim also participates in the Israeli inter-ministerial regulatory committee on medical cannabis. Over the years, Haim has initiated and contributed to numerous distinguished projects and programs in the field of narcotics abuse, prevention, and education.

Professor Raphael Mechoulam

Professor Mechoulam is an organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel.

He is an acclaimed scientist recognized for discovering the human endocannabinoid system and for isolating Tetrahydrocannabinol (THC), psychoactive component in Cannabis. In 1992, Professor Mechoulam and his team identified the endocannabinoid Anandamide, a neurotransmitter which has a similar effect on the body as THC.

Professor Mechoulam received his M.Sc. in biochemistry from the Hebrew University of Jerusalem and a Ph.D. from the Weizmann Institute. He completed postdoctoral studies at the Rockefeller Institute, New York. He has published some 390 scientific articles, holds about 25 patents, and is the recipient of numerous international awards and recognition.

In 1999 the International Cannabinoid Research Society (ICRS) established an annual award named The R. Mechoulam Annual Award in Cannabinoid Research.

Prof. Nachum Vaisman

A gastroenterologist and nutritional sciences expert. Nahum established and managed Israel’s first Clinical Nutrition Medical Center at Tel Aviv Sourasky Hospital and managed the Institute of Healthy Nutrition. He is a leading lecturer and researcher at the Tel Aviv University and Tel Aviv Medical Center and has published dozens of scientific articles in leading international magazines on the effects of nutrition on human health and disease prevention.

Prof. Itamar Raz

Professor Itamar Raz is head of the Israel National Diabetes Council and long time director of the diabetes unit at Hadassah University Medical Center. He also serves as the president of the Israel Diabetes Association, the head of the Israel National Council of Diabetes and president of D-Cure, a foundation that supports research in the field of diabetes. He is one of the world’s leading researchers and clinicians in diabetes, serving as the president of DIRECT  – Diabetes International Research and Educational Co-operative Team, a group of professional physicians from Central, Eastern and Southern Europe as well at the Mediterranean, who aim to develop ways to help prevent and control diabetes and enhance the quality of life of those suffering from diabetes. He serves on several advisory boards and is a member of several editorial boards, including the Israeli Medical Association Journal (IMAJ). Professor Raz received his M.D. from Hebrew University and completed post graduate studies at Hadassah Medical Center.

Prof. Simon Benita

Professor Simon Benita is the Former Director and Member of the Institute for Drug Research and the School of Pharmacy, Faculty of Medicine at The Hebrew University of Jerusalem, where he received his Ph.D. His research is focused on polymeric Nano and Microparticulate and lipid-based drug delivery systems aimed at improving ocular bioavailability, dermal penetration and drug targeting.

ron_kohen

Prof. Ron Kohen

Professor Ron Kohen is a biochemist, pharmacist and Professor of Pharmaceutics at the institute for Drug Research of the School of Pharmacy at the Hebrew University of Jerusalem.

He obtained his BSc and MSc in Pharmacy and Pharmaceutical Sciences and his PhD in Biochemistry all at the Hebrew University of Jerusalem. Following his doctoral studies, he joined Prof. Bruce Ames at the University of California Berkeley for his post-doctoral training. His research there focused on new natural antioxidants and their activity in the human body.

In 1989 he joined the School of Pharmacy at the Hebrew University of Jerusalem. Since then he has supervised the lab of Oxidative Stress, Free Radicals and Antioxidants. His research focuses on the beneficial and deleterious role of reactive oxygen species in health and diseases, the discovery of new antioxidant compounds, exploration of the role of new biochemical pathways against stress, elucidation of the mechanisms involved in ROS activity, and the targeting of specific sites and pathways to affect their activity.

In 2014 Prof. Kohen was elected Head of the School of Pharmacy and Director of the Institute for Drug Research.

Prof. Kohen is a member of the International Center for Cannabinoid Research at the Hebrew University. He is an author of more than 150 research articles and reviews, and 250 proceedings, abstracts and book chapters.

Principle Investigators

Professor Julio Wainstein

Professor Wainstein, a world renown expert on diabetes, is the founder and director of the diabetes unit  at Wolfson Mecial Center. He serves as chairman of Israel’s National Diabetes Council’s committee on the prevention of diabetes complications and is the former president of the Israel Diabetes. Dr. Wainstein has authored, coauthored or contributed to over a hundred scientific publications and has been involved in dozens of clinical trials in the field of diabetes medicine and research.

Dr. Adi Aran

Dr. Adi Aran serve as Head of the Pediatrics Neurology Department at Shaare Zedek Medical Center in Jerusalem. He recently launched a clinical trial to study the effects of medical cannabis on the behavior of autistic children and adults. Dr. Adi Aran, plans to test 120 low-to-medium functioning autistic individuals, aged 4 to 30 who will be given cannabis oils rich in cannabidiol (CBD), an active chemicals found in cannabis which is non-hallucinogenic. He has obtained the authorization in principle from the Israel Health Ministry for his tests. He is presently working on obtaining permits and finding subjects from other local hospitals, as well as from psychiatric facilities and centers dealing with childhood development.

Font Resize
Contrast